PFIZER INC (PFE.DE) Stock Price, Quote, News and Overview
FRA:PFE - Deutsche Boerse Ag - US7170811035 - Common Stock - Currency: EUR
PFE.DE Quote, Performance and Key Statistics
PFIZER INC
FRA:PFE (2/5/2025, 2:41:08 PM)
24.955
+0.1 (+0.4%)
The current stock price of PFE.DE is 24.955 EUR. In the past month the price decreased by -5.57%. In the past year, price decreased by -2.72%.
PFE.DE Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY.DE | ELI LILLY & CO | 82.11 | 767.05B | ||
| 1LLY.MI | ELI LILLY & CO | 79.43 | 741.99B | ||
| ZEG.DE | ASTRAZENECA PLC | 18.22 | 413.69B | ||
| NOV.DE | NOVO NORDISK A/S-B | 29.06 | 366.49B | ||
| JNJ.DE | JOHNSON & JOHNSON | 15.27 | 355.61B | ||
| 1JNJ.MI | JOHNSON & JOHNSON | 15.23 | 354.69B | ||
| 1SAN.MI | SANOFI | 14.78 | 260.95B | ||
| SAN.PA | SANOFI | 14.66 | 258.77B | ||
| SNW.DE | SANOFI | 14.58 | 257.34B | ||
| 1MRKX.MI | MERCK & CO. INC. | 16.39 | 238.80B | ||
| 6MK.DE | MERCK & CO. INC. | 15.16 | 220.84B | ||
| 1PFE.MI | PFIZER INC | 10.24 | 145.02B |
Related stock screener links
About PFE.DE
Company Profile
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The company is headquartered in New York City, New York and currently employs 88,000 full-time employees. The firm is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its Oncology products include Ibrance, Xtandi, Inlyta, Bosulif, Lorbrena, Braftovi, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio and Tivdak. Its primary care products include Eliquis, Nurtec ODT/Vydura, Comirnaty, the Prevnar family, Abrysvo, FSME/IMMUN-TicoVac, Paxlovid and Lucira by Pfizer. Its specialty care products include Xeljanz, Enbrel (outside the U.S. and Canada), Inflectra, Cibinqo, Litfulo, Vyndaqel family, Genotropin, Sulperazon, Zavicefta, Medrol and Panzyga.
Company Info
PFIZER INC
66 Hudson Boulevard East
New York City NEW YORK US
Employees: 88000
Company Website: https://www.pfizer.com/
Investor Relations: https://investors.pfizer.com
Phone: 12127332323
PFE.DE FAQ
What is the stock price of PFE.DE?
The current stock price of PFE.DE is 24.955 EUR.
What is the symbol for PFIZER INC stock?
The exchange symbol of PFIZER INC is PFE and it is listed on the Deutsche Boerse Ag exchange.
On which exchange is PFE.DE stock listed?
PFE.DE stock is listed on the Deutsche Boerse Ag exchange.
Is PFE.DE a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for PFE.DE, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of PFE.DE.
Does PFE.DE stock pay dividends?
PFE.DE has a dividend yield of 6.39%. The yearly dividend amount is currently 1.64.
When does PFE.DE stock report earnings?
PFE.DE will report earnings on 2025-02-04, before the market open.
What is the Price/Earnings (PE) ratio of PFE.DE?
The PE ratio for PFE.DE is 9.98. This is based on the reported non-GAAP earnings per share of 2.5 and the current share price of 24.955 EUR.
PFE.DE Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to PFE.DE. When comparing the yearly performance of all stocks, PFE.DE is a bad performer in the overall market: 78.57% of all stocks are doing better.
PFE.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to PFE.DE. While PFE.DE is still in line with the averages on profitability rating, there are concerns on its financial health.
PFE.DE Financial Highlights
Over the last trailing twelve months PFE.DE reported a non-GAAP Earnings per Share(EPS) of 2.5. The EPS decreased by -10.1% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 7.07% | ||
| ROA | 1.94% | ||
| ROE | 4.61% | ||
| Debt/Equity | 0.69 |
PFE.DE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 72% to PFE.DE. The Buy consensus is the average rating of analysts ratings from 30 analysts.
For the next year, analysts expect an EPS growth of 61.14% and a revenue growth 7.2% for PFE.DE